1. Home
  2. KNOP vs SENS Comparison

KNOP vs SENS Comparison

Compare KNOP & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KNOT Offshore Partners LP

KNOP

KNOT Offshore Partners LP

HOLD

Current Price

$10.37

Market Cap

380.1M

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$7.23

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNOP
SENS
Founded
2013
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Industrial Machinery/Components
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
380.1M
301.2M
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
KNOP
SENS
Price
$10.37
$7.23
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$18.38
AVG Volume (30 Days)
93.5K
512.8K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,389,000.00
Revenue This Year
$3.51
$74.15
Revenue Next Year
N/A
$58.60
P/E Ratio
$9.00
N/A
Revenue Growth
N/A
19.85
52 Week Low
$6.16
$0.41
52 Week High
$11.78
$8.75

Technical Indicators

Market Signals
Indicator
KNOP
SENS
Relative Strength Index (RSI) 38.25 62.40
Support Level $10.04 $7.35
Resistance Level $10.88 $7.57
Average True Range (ATR) 0.32 0.46
MACD -0.07 0.06
Stochastic Oscillator 2.11 78.03

Price Performance

Historical Comparison
KNOP
SENS

About KNOP KNOT Offshore Partners LP

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: